ES2156215T3 - Utilizacion de un conjugado en el tratamiento y/o diagnostico de enfermedades inflamatorias. - Google Patents
Utilizacion de un conjugado en el tratamiento y/o diagnostico de enfermedades inflamatorias.Info
- Publication number
- ES2156215T3 ES2156215T3 ES95933300T ES95933300T ES2156215T3 ES 2156215 T3 ES2156215 T3 ES 2156215T3 ES 95933300 T ES95933300 T ES 95933300T ES 95933300 T ES95933300 T ES 95933300T ES 2156215 T3 ES2156215 T3 ES 2156215T3
- Authority
- ES
- Spain
- Prior art keywords
- pct
- conjugate
- diseases
- diagnosis
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
LA INVENCION SE REFIERE A LA UTILIZACION DE UN CONJUGADO QUE INCLUYE UN PRINCIPIO ACTIVO, UN AGLUTINANTE Y UN SOPORTE, PARA LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO Y/O DIAGNOSTICO DE ENFERMEDADES INFLAMATORIAS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4435087A DE4435087A1 (de) | 1994-09-30 | 1994-09-30 | Konjugat zur Behandlung von Infektions-, Autoimmun- und Hauterkrankungen |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2156215T3 true ES2156215T3 (es) | 2001-06-16 |
Family
ID=6529687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES95933300T Expired - Lifetime ES2156215T3 (es) | 1994-09-30 | 1995-09-26 | Utilizacion de un conjugado en el tratamiento y/o diagnostico de enfermedades inflamatorias. |
Country Status (7)
Country | Link |
---|---|
US (1) | US5906977A (es) |
EP (1) | EP0799054B1 (es) |
JP (1) | JPH10506398A (es) |
AT (1) | ATE198990T1 (es) |
DE (2) | DE4435087A1 (es) |
ES (1) | ES2156215T3 (es) |
WO (1) | WO1996010422A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5612034A (en) * | 1990-10-03 | 1997-03-18 | Redcell, Inc. | Super-globuling for in vivo extended lifetimes |
DE19505960A1 (de) * | 1995-02-21 | 1996-08-22 | Deutsches Krebsforsch | Konjugat zur individuellen Dosierung von Arzneimitteln |
DE19514087A1 (de) * | 1995-04-13 | 1996-10-17 | Deutsches Krebsforsch | Konjugat aus einem Wirkstoff, einem Polyether und ggfs. einem nicht als körperfremd angesehenen, nativen Protein |
DE19627164C2 (de) * | 1996-07-05 | 1998-09-24 | Deutsches Krebsforsch | Herstellung polyether-aufweisender Chlorine und Bakteriochlorine, solche Verbindungen und ihre Verwendung |
US5942534A (en) * | 1996-10-10 | 1999-08-24 | The General Hospital Corporation | Photodynamic therapy for the treatment of osteoarthritis |
DE19814405C2 (de) * | 1998-03-31 | 2000-03-02 | Schastak Astrid | Porphyrine und ihre Verwendung als Photosensitizer |
US20020137901A1 (en) * | 2001-01-22 | 2002-09-26 | Cavanaugh Philip Gerard | Synthesis, and photodynamic therapy-mediated anti-cancer, and other uses of chlorin e6-transferrin |
PL367244A1 (en) * | 2001-05-15 | 2005-02-21 | Faulk Pharmaceuticals, Inc. | Targeted delivery of drugs for the treatment of viral infections |
WO2002094271A1 (en) * | 2001-05-15 | 2002-11-28 | Faulk Pharmaceuticals, Inc. | Targeted delivery of bioaffecting compounds for the treatment of cancer |
US6756354B2 (en) * | 2001-09-05 | 2004-06-29 | Deanna Jean Nelson | Therapeutic compositions containing oligo (ethylene glycol)-terminated 1,2-dithiolanes and their conjugates |
US20040192665A1 (en) * | 2002-08-02 | 2004-09-30 | Slil Biomedical Corporation | Conjugates of porphyrin compounds with chemotherapeutic agents |
US8993614B2 (en) | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
CA3028122A1 (en) | 2016-06-16 | 2017-12-21 | Oncoselect Therapeutics, Llc | Porphyrin compounds and compositions useful for treating cancer |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE882541A (fr) * | 1980-03-31 | 1980-07-16 | Inst Internat De Pathologie Ce | Nouvelles formes pharmaceutiques leur preparation et les compositions qui les contiennent |
US4466951A (en) * | 1982-11-12 | 1984-08-21 | University Of California | Intracellular trapping of therapeutics or tracer agents |
US4596674A (en) * | 1984-09-11 | 1986-06-24 | Merck & Co., Inc. | Immunogenic HAV peptides |
FI102355B (fi) * | 1988-02-11 | 1998-11-30 | Squibb Bristol Myers Co | Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjug aattien valmistamiseksi |
US5308604A (en) * | 1989-04-19 | 1994-05-03 | Deutsches Krebsforschungsinstitut | Conjugates for tumor localization and/or tumor therapy |
DE3912792A1 (de) * | 1989-04-19 | 1990-10-25 | Hoechst Ag | Konjugate zur tumorlokalisation und/oder tumortherapie, verfahren zu ihrer herstellung sowie diese enthaltende diagnostika und/oder therapeutika |
DE4017439C2 (de) * | 1990-05-30 | 1994-06-23 | Deutsches Krebsforsch | Polyethersubstituierte Tumormittel |
US5622685A (en) * | 1990-05-30 | 1997-04-22 | Deutches Krebsforchunszentrum Stiftung Des Offentlichen Rechts | Polyether-substituted porphyrin anti-tumor agents |
CA2047031A1 (en) * | 1990-07-19 | 1992-01-20 | Stephen Marburg | Peptide-polysaccharide-protein conjugate vaccines |
WO1992016232A1 (en) * | 1991-03-12 | 1992-10-01 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Polysaccharide-protein conjugates |
DE4115038A1 (de) * | 1991-05-08 | 1992-11-12 | Genentech Inc | Neue konjugate, bestehend aus einem glykoprotein und einer nukleinsaeure-bindenden substanz |
US5328985A (en) * | 1991-07-12 | 1994-07-12 | The Regents Of The University Of California | Recombinant streptavidin-protein chimeras useful for conjugation of molecules in the immune system |
EP0601183A4 (en) * | 1991-08-02 | 1996-12-04 | Meiji Milk Prod Co Ltd | ANTI-HIV MEDICINE. |
US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
-
1994
- 1994-09-30 DE DE4435087A patent/DE4435087A1/de not_active Ceased
-
1995
- 1995-09-26 JP JP8511275A patent/JPH10506398A/ja active Pending
- 1995-09-26 EP EP95933300A patent/EP0799054B1/de not_active Expired - Lifetime
- 1995-09-26 US US08/817,678 patent/US5906977A/en not_active Expired - Fee Related
- 1995-09-26 WO PCT/DE1995/001337 patent/WO1996010422A1/de active IP Right Grant
- 1995-09-26 ES ES95933300T patent/ES2156215T3/es not_active Expired - Lifetime
- 1995-09-26 DE DE59509007T patent/DE59509007D1/de not_active Expired - Fee Related
- 1995-09-26 AT AT95933300T patent/ATE198990T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0799054B1 (de) | 2001-01-31 |
US5906977A (en) | 1999-05-25 |
ATE198990T1 (de) | 2001-02-15 |
EP0799054A1 (de) | 1997-10-08 |
WO1996010422A1 (de) | 1996-04-11 |
DE59509007D1 (de) | 2001-03-08 |
JPH10506398A (ja) | 1998-06-23 |
DE4435087A1 (de) | 1996-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1037673A4 (en) | CHARGED LIPIDS AND THE USE THEREOF | |
ES2156215T3 (es) | Utilizacion de un conjugado en el tratamiento y/o diagnostico de enfermedades inflamatorias. | |
KR960701051A (ko) | 이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases) | |
DK0841949T3 (da) | Anvendelse af saccharid-konjugater | |
EA200000848A1 (ru) | Способ селективного снижения числа или активности макрофагов (варианты), способ лечения или профилактики заболевания субъекта (варианты), способ диагностики заболевания у субъекта | |
EP0671920A4 (en) | AN ANTI-IDIOTYPICAL ANTIBODY AND ITS USE IN THE DIAGNOSIS AND THERAPY OF HIV-RELATED DISEASES. | |
DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
ATE123943T1 (de) | Mittel zur behandlung und vorbeugung von bauchentzündungen, die als wirkstoff zink-l- carnosin-salze oder -komplexe enthalten. | |
EP1140170A4 (en) | NOVEL AGENTS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF EYE DISORDERS | |
ES2184800T3 (es) | Uso de agentes anti-vegf en el tratamiento de la endometriosis. | |
EA200300507A1 (ru) | Радиофармацевтические агенты для диагностики болезни альцгеймера | |
CY1109868T1 (el) | Cd81 πρωτεϊνη υποδοχεας ηπατιτιδας c | |
FI972703A0 (fi) | Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia | |
EE03262B1 (et) | Imidaso[1,2-a]püridiinidest saadavad alkoksüalküülkarbamaadid, nende valmistamine ja kasutamine | |
PT841939E (pt) | Agentes terapeuticos e doencas auto-imunes | |
ATE81467T1 (de) | Immunosuppression bei der auf immunotoxin basierten behandlung von menschen. | |
MXPA00010254A (es) | Tratamiento de disfuncion sexual en ciertos grupos de pacientes. | |
DK0821593T3 (da) | Konjugat af et aktivt middel, et protein og eventuelt et for kroppen ikke som fremmed anset nativt protein | |
ID23184A (id) | Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi | |
DE69829995D1 (de) | Multivalente rekombinante antikörper zur behandlung von hrv infektionen | |
TR199500984A2 (tr) | Selegilin'in epileptik hastaliklarin tedavisinde kullanimi. | |
ATE271867T1 (de) | Behandlung der harninkontinenz und zusammenstellung dafür | |
GB9723630D0 (en) | M.vaccae preparation and its use | |
ZA983211B (en) | Use of mizolastine for preparing medication for the treatment of inflammation | |
ES2181160T3 (es) | Derivados de 1,4-dihidropiridina y su utilizacion en terapia. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 799054 Country of ref document: ES |